MARKET

ARTV

ARTV

ARTIVA BIOTHERAPEUTICS INC
NASDAQ
3.960
-0.050
-1.25%
After Hours: 4.010 +0.05 +1.26% 19:30 11/16 EST
OPEN
3.980
PREV CLOSE
4.010
HIGH
4.065
LOW
3.925
VOLUME
1.31M
TURNOVER
--
52 WEEK HIGH
14.53
52 WEEK LOW
2.960
MARKET CAP
195.75M
P/E (TTM)
-1.3220
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ARTV last week (1109-1113)?
Weekly Report · 1d ago
ARTV Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Artiva Biotherapeutics, Inc. (ARTV)
Barchart · 4d ago
Artiva Biotherapeutics Estimates $10M-$15M In Contract Termination And Other Costs For AlloNK Trials; Estimates $17M-$20M In Costs Related To Workforce Reduction
Benzinga · 11/09 22:18
Weekly Report: what happened at ARTV last week (1102-1106)?
Weekly Report · 11/09 09:15
Weekly Report: what happened at ARTV last week (1026-1030)?
Weekly Report · 11/02 09:15
Weekly Buzz: ABBV, PFE Win FDA Nod; ARTV Slashes Jobs; DAVI, SGRY Strike Deals
NASDAQ · 10/30 16:56
Deal Dispatch: DoorDash Buys Instacart For $17B, Thrive Holdings Acquires ADT, SalesForce Nabs Rune Technologies
Benzinga · 10/30 16:49
Artiva Biotherapeutics Price Target Announced at $4.00/Share by Jefferies
Dow Jones · 10/29 22:34
More
About ARTV
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Its product candidates are derived from donor cells (allogeneic) rather than a patient's own cells (autologous) and are pre-manufactured, stored frozen and ready to ship to a patient's treatment location. Its lead product candidate, AlloNK, is being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in patients with autoimmune diseases and cancers, such as systemic lupus erythematosus (SLE), lupus nephritis (LN), RA, PV, the ANCA-associated vasculitis subtypes GPA/MPA, and B-NHL. AlloNK is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted mAbs in an ongoing Phase I/Ib trial in SLE with or without LN and a basket investigator-initiated trial (IIT) in multiple autoimmune indications.

Webull offers Artiva Biotherapeutics Inc stock information, including NASDAQ: ARTV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARTV stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ARTV stock methods without spending real money on the virtual paper trading platform.